Therapeutic Asset Ratings

361 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Sevoflurane Obesity	Ataturk University	P4	B (58)
URSODEOXYCHOLIC ACID Obesity	Ain Shams University	P4	B (58)
CAFFEINE Obesity	Boehringer Ingelheim	P3	B (58)
cx11 Obesity	Corxel Pharmaceuticals	P3	B (58)
Eloralintide Obesity	Eli Lilly and Company	P3	B (58)
hdm1005 Obesity	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	P3	B (58)
Maridebart Cafraglutide Obesity	Amgen	P3	B (58)
met097 Obesity	Pfizer	P3	B (58)
nnc0487-0111 Obesity	Novo Nordisk A/S	P3	B (58)
pf-08653944 Obesity	Pfizer	P3	B (58)
ray1225 Obesity	Guangdong Raynovent Biotech Co., Ltd	P3	B (58)
Irbesartan Obesity	Hippocration General Hospital	P4	B (57)
Calcined Magnesia Obesity	Coordinación de Investigación en Salud, Mexico	P3	B (57)
EFPEGLENATIDE Obesity	Hanmi Pharmaceutical Company Limited	P3	B (57)
PITAVASTATIN Obesity	Hoffmann-La Roche	P3	B (57)
HUMAN FAECAL MATTER Obesity	Institut Pasteur	P2	B (57)
Alpelisib Obesity	Columbia University	P4	B (56)
Hcg Obesity	The Second Hospital of Shandong University	P4	B (56)
HEPARIN Obesity	National and Kapodistrian University of Athens	P4	B (56)
Lamivudine Obesity	José Antonio Mata Marín	P4	B (56)
Plavix Obesity	Fundació d'investigació Sanitària de les Illes Balears	P4	B (56)
TENOFOVIR DISOPROXIL FUMARATE Obesity	José Antonio Mata Marín	P4	B (56)
UMBELLATINE Obesity	China National Center for Cardiovascular Diseases	P4	B (56)
Ixekizumab Obesity	NHS Greater Glasgow and Clyde	P3	B (56)
MAGNESIUM METALLICUM Obesity	University of Sao Paulo General Hospital	P3	B (56)

Showing 76 to 100 of 361 assets